Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Current Assets (2016 - 2025)

Capricor Therapeutics has reported Current Assets over the past 15 years, most recently at $322.9 million for Q4 2025.

  • Quarterly results put Current Assets at $322.9 million for Q4 2025, up 97.66% from a year ago — trailing twelve months through Dec 2025 was $322.9 million (up 97.66% YoY), and the annual figure for FY2025 was $322.9 million, up 97.66%.
  • Current Assets for Q4 2025 was $322.9 million at Capricor Therapeutics, up from $101.0 million in the prior quarter.
  • Over the last five years, Current Assets for CAPR hit a ceiling of $322.9 million in Q4 2025 and a floor of $29.5 million in Q3 2023.
  • Median Current Assets over the past 5 years was $47.0 million (2022), compared with a mean of $77.2 million.
  • Biggest five-year swings in Current Assets: crashed 37.84% in 2023 and later skyrocketed 304.73% in 2025.
  • Capricor Therapeutics' Current Assets stood at $36.4 million in 2021, then increased by 17.71% to $42.9 million in 2022, then rose by 18.58% to $50.9 million in 2023, then soared by 221.27% to $163.4 million in 2024, then surged by 97.66% to $322.9 million in 2025.
  • The last three reported values for Current Assets were $322.9 million (Q4 2025), $101.0 million (Q3 2025), and $124.1 million (Q2 2025) per Business Quant data.